Immunosuppression with Rituximab in Glomerular Diseases in Adults: Who, How and When?
Rituximab, a monoclonal antibody with the ability to bind itself to CD20, leads to a rapid depletion of B-cells (in around 24-72 hours), limiting antibody formation. The marker CD20 does not exist in any other cell type, which makes the action of rituximab specific. This antibody has been used in a...
Main Authors: | Raquel Pereira Sousa Pinto, Carolina dos Reis Ferreira, André Sotero Araújo Ferreira, Joaquim Manuel Leal Milheiro, Catarina Maia da Veiga, Maria Luísa de Lemos Ferreira Casimiro da Costa, Andreia Raquel Dias da Silva, Carla Maria Pereira Lima, Sérgio José da Silva Lemos |
---|---|
Format: | Article |
Language: | English |
Published: |
Publicações Ciência e Vida
2023-06-01
|
Series: | Revista Portuguesa de Nefrologia e Hipertensão |
Subjects: | |
Online Access: | https://spnefro.pt/_doi/reference/cbe0a333-3a31-4926-a522-7e725cad311a |
Similar Items
-
Hepatitis B Surface Antibody (Anti-HBs) Kinetics during Rituximab Chemotherapy and Performance of Hepatitis B Vaccine before Immunosuppression: Two Prospective Studies
by: João Marcello de Araujo-Neto, et al.
Published: (2022-08-01) -
Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia
by: Ben Koszegi, et al.
Published: (2023-03-01) -
Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months
by: Kamran Balighi, et al.
Published: (2019-05-01) -
A therapeutic perspective for refractory polymyositis to corticosteroids and immunosuppressant drugs: A case report
by: Dilceu Silveira Tolentino Junior
Published: (2021-02-01) -
Clinical analysis of rituximab for adult refractory primary membranous nephropathy
by: FENG Linhong, et al.
Published: (2023-03-01)